NCT06875193View on ClinicalTrials.gov

DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Type2diabetes
Interventions
DRUG

DW6012(Dasidiem tab. 10/100mg)

Once a day, Oral administration

Trial Locations (1)

Unknown

RECRUITING

Kyung Hee University Hospital at Gangdong, Seoul

Sponsors
All Listed Sponsors
lead

Dong Wha Pharmaceutical Co. Ltd.

INDUSTRY